Semaglutide's ATC Code and What It Tells You About the Medicine

You've searched for an ATC code, here's the full picture behind those six characters

Imagine you're a hospital pharmacist cross-checking a patient's drug chart, or a researcher pulling prescribing data from a national database. The name "semaglutide" could refer to a 0.5 mg Ozempic pen for diabetes or a 2.4 mg Wegovy injection for obesity, two very different clinical stories. The ATC code cuts through that ambiguity. A10BJ06 is semaglutide's unique identifier in the Anatomical Therapeutic Chemical classification, maintained by the WHO Collaborating Centre for Drug Statistics Methodology. Breaking it down: A = alimentary tract and metabolism; A10 = drugs used in diabetes; A10B = blood-glucose-lowering drugs, excluding insulins; A10BJ = GLP-1 receptor agonists; A10BJ06 = semaglutide specifically.

The code was assigned when semaglutide first received authorisation as a diabetes medicine. It has not changed as the drug gained additional indications, weight management, cardiovascular risk reduction, and (from 3 July 2026) a conditional UK approval for MASH, a form of fatty liver disease. ATC codes travel with the molecule, not the brand. That is why Ozempic and Wegovy share A10BJ06 even though their licensed uses, doses and patient populations differ substantially. The clinical profile of semaglutide across these indications is worth understanding if you are trying to make sense of what you have been prescribed or are considering.

One practical consequence: when the MHRA or NHS England publish safety updates or prescribing data using ATC codes, every semaglutide product is gathered under A10BJ06. That pooled surveillance is part of how post-marketing safety signals (including the January 2026 Drug Safety Update on pancreatitis risk across GLP-1 medicines) are detected and communicated to prescribers.

Why the same ATC code appears on a diabetes pen and a weight-loss medicine

The confusion is understandable. You search for semaglutide's ATC code because you have seen it on a medicine box, a patient information record, or a clinical document, and you are trying to work out whether the product you are looking at is meant for diabetes, weight loss, or something else. The ATC system cannot answer that question on its own, you need to look at the brand name, strength and licensed indication alongside the code.

Wegovy injection (0.25 mg to 2.4 mg, or up to 7.2 mg on the newer pen approved by the MHRA in April 2026) and Wegovy tablets (1.5 mg to 25 mg, the first oral GLP-1 licensed for weight management in the UK, approved in June 2026) both carry A10BJ06 and are licensed for weight management. Ozempic (0.5 mg, 1 mg, 2 mg) also carries A10BJ06 but is licensed for type 2 diabetes, it is not authorised for weight loss, and presenting it as such would be clinically and legally inaccurate. The NHS medicines page for semaglutide explains the distinctions clearly and is a useful first reference for patients trying to identify which product applies to them.

Rybelsus, the oral semaglutide tablet for type 2 diabetes, also sits under A10BJ06, but its doses (3 mg, 7 mg, 14 mg) and indication are entirely separate from the Wegovy tablet's 1.5 mg to 25 mg weight-management schedule. The code is the same; the clinical purpose is not. If you are reading an ATC code on a box and want to understand what the medicine is actually for, the patient information leaflet inside the pack is the authoritative source, it sets out the indication, dose schedule and who it is licensed for.

What ATC codes mean for prescribing, safety reporting and your records

In everyday clinical practice in the UK, ATC codes rarely appear on the prescription or dispensing label a patient sees. They live in the background: in pharmacy management systems, Summary Care Records, hospital formularies and the Yellow Card pharmacovigilance database. When your GP or prescriber reviews your medication list, they are working from brand names and doses. But behind those records, A10BJ06 is grouping your semaglutide alongside every other patient prescribed the molecule, feeding into the national picture of how the drug is being used and what effects are being reported.

That matters practically. The MHRA's ability to identify safety signals (say, a clustering of reports of a particular adverse effect at a new dose) depends on accurate ATC-coded data flowing from dispensing records. Patients can contribute directly by reporting unexpected side effects via the Yellow Card scheme, the UK's official mechanism for adverse drug reaction reporting. It takes minutes and genuinely feeds into post-market surveillance for medicines like semaglutide that are still under additional monitoring (Black Triangle status) while real-world data accumulates.

For those exploring semaglutide for weight management specifically, understanding the code is a starting point, the next step is understanding whether Wegovy, in injection or tablet form, is clinically suitable for you. Eligibility, current health, medicines interactions and lifestyle factors all inform that decision. Our clinical team at nume reviews every consultation personally; you can read more about the prescribers behind those decisions on the clinical team page. A sense of what private treatment costs in the UK is covered on our Wegovy pricing page, and if you are wondering whether any savings are available, we explain how a Wegovy promo code can be applied to your order, alongside details of the current Wegovy code we accept at checkout, and guidance on the Wegovy CPT code that may be relevant if you are navigating insurance or private healthcare claims. If you have broader questions about how online weight-loss treatment works, our FAQs are a practical place to start.

Ready to find out whether treatment is right for you? Check your eligibility with a free consultation, reviewed the same day by one of our GPhC-registered prescribers.